Bharath Takulapalli has over 13 years of multidisciplinary research experience at the interface of nanotechnology and molecular biology, and is the principal inventor of INanoBio sensor technologies. He has authored multiple publications and patents in the areas of nano sensors, nanotechnology, genome sequencing and protein arrays. With doctoral training in solid state electronics, electrical engineering and molecular sensors, over the past ten years he has worked on developing technology solutions to personalized healthcare of the future. He has adjunct scientist affiliation with The Biodesign Institute at ASU. Dr. Takulapalli has a bachelor’s from IIT Madras India, and PhD from Arizona State University in Tempe.
Mukil Mohan has more than twelve years of experience in systems engineering and management. With a background in both electrical engineering and management, he develops operational and business strategies to complement INanoBio’s technology and product development roadmaps. He has extensive experience leading high productivity cross functional teams. He has a Master’s degree in Electrical Engineering from the Ira A. Fulton School of Engineering and an MBA from the W.P. Carey School of Business both at Arizona State University in Tempe.
Jim Walker brings with him over 30 years of experience in financial management and fundraising. He has previously served as CFO for many early to late stage companies. In addition to financial roles he has served in operational roles at many technology companies, including companies in medical and healthcare diagnostics fields. He was senior executive and Chairman of Board of Alara Inc until 2004, and its President and CEO until 2011. Prior to that he held leadership positions at AlphaSmart, Diamond Multimedia Systems, Fujitsu Computer Products and Fujitsu America.
Moneesh Chatterjee has over 25 years of interdisciplinary experience in biotechnology, pharmaceutical drug discovery and chemical engineering. Prior to joining INanoBio he served as Global Lead for Search & Evaluation in the Strategic Transactions Group at Bristol-Myers Squibb. Earlier, he was group leader of the Compound Management team that supported the entire drug discovery effort at BMS including high throughput screening and lead optimization for various classes of targets. He has a PhD in bioorganic chemistry from Stony Brook University, NY and he did his post-doctoral research at the John Hopkins University.
Carl Yamashiro has over 25 years of experience in biotech product development, in vitro diagnostics and large program management. Previously, he served in the roles in academia of acting Director of the Center for Healthcare Innovation & Clinical Trials and as Acting Director of the Research Management Office at Biodesign Institute, at ASU. His industrial experience spans research management roles at Motorola, Amersham (now part of GE Healthcare), Roche and Applied Biosystems. Dr. Yamashiro has a Ph.D. in Molecular Biology from the University of Oregon and was an American Cancer Society Postdoctoral Fellow at Stanford University.